ClinicalTrials.gg
CompletedNCT00757042Updated Sep 21, 2022Results posted

Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis

A Phase 1 interventional study of Tezepelumab and Placebo in Atopic Dermatitis and Healthy Volunteers, sponsored by Amgen. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Dermatitis, Atopic by Amgen — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · Amgen.

Enrollment
13th of 15
78 · median 231
Started
2008
the only one that year
Phase 1
5 of 15
none open now
Registered
1st of 15
by date

Among the 15 studies in Dermatitis, Atopic by Amgen, this one is the 13th largest by enrollment, is the only one that started in 2008, is one of 5 in phase 1, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 15 studies in Dermatitis, Atopic by Amgen is open now. The open studies under Dermatitis, Atopic, anywhere →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Dermatitis, Atopic by Amgen as a file.
02

Study summary

This study is a single dose escalation study of tezepelumab (AMG 157) in healthy adults (Part A) and adults with moderate to severe atopic dermatitis (Part B). The purpose of the study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of tezepelumab.

03

Conditions studied

  • Atopic Dermatitis
  • Healthy Volunteers

Keywords

  • atopic dermatitis
  • skin diseases
  • healthy volunteer
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must sign an Institutional Review Board (IRB) approved form before any study specific procedures
  • Subjects must be aged between 18 and 45 years, inclusive (Part A only)
  • Female subjects must be of non-
  • Male subjects with partners of should inform their partner of their participation in this clinical study and use highly effective methods of during the study
  • Healthy subjects must have a (BMI) between 18 to 32 kg/m\^2, inclusive
  • Subject must have normal or clinically acceptable physical examination, clinical laboratory tests and (ECG) results
  • For Part B, subject must have active atopic dermatitis (AD) affecting ≥ 10% body surface area; Eczema Area and Severity Index (EASI) score ≥ 15, aged between 18 and 60 years, inclusive and BMI between 18 and 35 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

  • Subject who has history or evidence of a disorder, condition or disease that, in the opinion of the Investigator in consultation with the Amgen physician, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
  • Subject who has evidence of any active or suspected bacterial, viral, fungal or parasitic infections within the past 30 days prior to randomization
  • Subject who has known positive tuberculin skin test or recent (within 6 months from randomization) exposure to an individual with active tuberculosis
  • Subject who has history of within 5 years before randomization
  • Subject who has history of significant dermatological conditions (except for atopic dermatitis in Part B)
  • Subject who has previously received any drug (or is currently using an investigational device) within 30 days prior to randomization
  • Subject who has tested positive for drugs and/or alcohol use at screening or before randomization
  • Female subjects who are pregnant or lactating
  • Subject who has used nicotine or tobacco containing products during 6 months before randomization and during the study (except for Part B below)
  • Subject has known type I/II diabetes
  • Subject used nonprescription drugs within 14 days prior to randomization and during the study
  • Subject used any cytotoxic or drugs with 30 days or 5 half-lives prior to randomization and during the study
  • Subject previously received a monoclonal antibody
  • Subject donated blood or had loss of blood of equal to or greater than 500 mL with 2 months of screening
  • Subject positive for antibodies, surface antigen, or antibodies
  • Subject has any condition that might compromise or compliance to the protocol
  • For atopic dermatitis subjects in Part B (Cohorts 9 and 10) only, additional exclusion criteria are as follows:
  • Subject who has concurrent skin disease (eg, acne) of such severity in the study area that it could interfere with study evaluation;
  • Subject who has active or recent skin infections (within 7 days of randomization);
  • Subject who has received phototherapy (eg, ultraviolet [UV] A, UVB) known or suspected to have an effect on AD within 6 weeks prior to randomization;
  • Subject who has received by other than topical, inhaled or intranasal delivery within 4 weeks prior to randomization;
  • Subject who has been treated with topical calcineurin inhibitors within 14 days prior to randomization;
  • Subject who uses any medications that interfere with blood coagulation (eg nonsteroidal anti-inflammatory drugs [NSAIDs]) or wound healing within 7 days or 5 half-lives (whichever is longer) prior to enrolling into the study and for the duration of the study.
  • Subject who smokes more than 10 cigarettes per day within the 6 months prior to randomization and during the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Participants will receive a single dose of tezepelumab administered subcutaneously or intravenously. The starting dose will be 2.1 mg tezepelumab.

    Drug: Tezepelumab

  • Placebo comparator
    Placebo

    Participants will receive matching placebo administered subcutaneously or intravenously.

    Drug: Placebo

Interventions

  • Administered by subcutaneous or intravenous injection

    Also known as: AMG 157, Tezspire

  • DrugPlacebo

    Matching placebo administered by subcutaneous or intravenous injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Adverse events (AEs) include any untoward medical occurrence in a trial participant administered a study drug and does not necessarily have a causal relationship with this treatment. AEs include worsening of a pre-existing medical condition and laboratory value changes requiring therapy or adjustment in prior therapy. AEs were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 3, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening AE and Grade 5 = death due to AE. Relationship to study treatment was determined by the investigator. A serious adverse event (SAE) is defined as an AE that met 1 or more of below criteria: * was fatal; * was life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * was a congenital anomaly/birth defect; * other significant medical hazard.

    Time frame: For Part A Tezepelumab/Placebo 2.1 mg, 7 mg, 21 mg, 70 mg, and 210 mg SC: 85 days. For Part A Tezepelumab/Placebo 420 mg SC, 210 mg IV, and 700 mg IV and Part B: 113 days

  2. Number of Participants Who Developed Anti-tezepelumab Antibodies

    All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab. The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.

    Time frame: Blood samples for the measurement of antibodies were collected on Days 29, 57, 85, and (for cohorts who received 420 mg Tezepelumab/placebo SC or any IV dose) 113.

Secondary outcomes

  1. Part A: Time of Maximum Observed Concentration (Tmax) of Tezepelumab

    The time at which the maximum concentration of tezepelumab was observed was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.

  2. Part A: Maximum Observed Concentration (Cmax) of Tezepelumab

    The maximum observed serum concentration of tezepelumab was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.

  3. Part A: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab

    The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.

  4. Part A: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab

    The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.

  5. Part A: Elimination Half-life (t1/2) of Tezepelumab

    Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.

  6. Part B: Time of Maximum Observed Concentration (Tmax) of Tezepelumab

    Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.

  7. Part B: Maximum Observed Concentration (Cmax) of Tezepelumab

    Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.

  8. Part B: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab

    The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.

  9. Part B: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab

    The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.

  10. Part B: Elimination Half-life (t1/2) of Tezepelumab

    Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

    Time frame: Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.

  11. Part B: Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Eczema Area and Severity Index (EASI 50) Score

    EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = \< 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.

    Time frame: Baseline and days 15, 29, 43, 57, 85, and 113

  12. Part B: Percentage of Participants Achieving at Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) Score

    EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = \< 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.

    Time frame: Baseline and days 15, 29, 43, 57, 85, and 113

  13. Part B: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score

    EASI is a tool used to measure the severity of AD. The index involves an assessment of the intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale from 0 (none) to 3 (severe). The percent affected area for each of the 4 body areas is assessed on a 6-point scale from 0 (0%) to 6 (90% to 100%). The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score is the sum of the scores for each body region, and ranges from 0 to 72, with higher scores indicating greater disease severity. Percent change from baseline = \[(Post-baseline Value - Baseline Value) / Baseline Value\] x 100. A negative change from baseline indicates improvement.

    Time frame: Baseline and days 15, 29, 43, 57, 85, and 113

  14. Part B: Change From Baseline in Investigator's Global Assessment (IGA)

    IGA score is a static 6-point measure of disease activity based on an overall assessment of skin lesions. The IGA was scored on a scale of 0 to 5, where 0 (clear) = no inflammatory signs of AD; 1. (almost clear) = just perceptible erythema and just perceptible papulation/infiltration; 2. (mild) = mild erythema and mild papulation and infiltration; 3. (moderate) = moderate erythema and moderate papulation and infiltration; 4. (severe) = severe disease with severe erythema and severe papulation and infiltration; 5. (very severe) = severe disease with severe erythema and severe papulation and infiltration with oozing/crusting. A negative change from baseline indicates improvement.

    Time frame: Baseline and days 15, 29, 43, 57, 85, and 113

07

Results

Posted Jul 18, 2022

Participant flow

This study was a single-ascending dose (SAD) study of tezepelumab in healthy adults (Part A; Cohorts 1-8) and adults with moderate to severe atopic dermatitis (AD) (Part B; Cohort 9). The study was conducted at seven centers in the United States, including one center that conducted the testing in all healthy adults and six centers that performed the study in AD participants. Dose escalation was based on blinded review of safety data up to day 15 from the previous cohort.

Participant flow — Overall Study
MilestonePart A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IVPart A: PlaceboPart B: Tezepelumab 700 mg IVPart B: Placebo IV
Started6666666616104
Received study drug666666661693
Completed666666661593
Not completed00000000111
Withdrew: Lost to follow-up00000000100
Withdrew: Ineligibility determined00000000001
Withdrew: Withdrawal by subject00000000010

Outcome measures

PrimaryNumber of Participants With Adverse Events

Adverse events (AEs) include any untoward medical occurrence in a trial participant administered a study drug and does not necessarily have a causal relationship with this treatment. AEs include worsening of a pre-existing medical condition and laboratory value changes requiring therapy or adjustment in prior therapy. AEs were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 3, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening AE and Grade 5 = death due to AE. Relationship to study treatment was determined by the investigator. A serious adverse event (SAE) is defined as an AE that met 1 or more of below criteria: * was fatal; * was life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * was a congenital anomaly/birth defect; * other significant medical hazard.

Time frame:
For Part A Tezepelumab/Placebo 2.1 mg, 7 mg, 21 mg, 70 mg, and 210 mg SC: 85 days. For Part A Tezepelumab/Placebo 420 mg SC, 210 mg IV, and 700 mg IV and Part B: 113 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPart A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IVPart A: Placebo SCPart A: Placebo IVPart B: Tezepelumab 700 mg IVPart B: Placebo IV
Any adverse event351623458373
Serious adverse event000000000001
AE leading to study drug discontinuation000000000000
AE leading to discontinuation from study000000000000
Fatal adverse event000000000000
Treatment-related adverse event100021204133
SecondaryPart A: Time of Maximum Observed Concentration (Tmax) of Tezepelumab

The time at which the maximum concentration of tezepelumab was observed was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.
Reported as:
Median · hours
Part A: Time of Maximum Observed Concentration (Tmax) of Tezepelumab
hoursPart A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IV
Part A: Time of Maximum Observed Concentration (Tmax) of Tezepelumab190.94 (117.87 to 332.15)237.09 (140.50 to 335.07)142.10 (117.43 to 336.10)130.87 (69.27 to 237.90)93.65 (70.22 to 359.17)80.89 (68.27 to 116.58)1.13 (1.08 to 8.00)1.04 (1.02 to 1.17)
PrimaryNumber of Participants Who Developed Anti-tezepelumab Antibodies

All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab. The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.

Time frame:
Blood samples for the measurement of antibodies were collected on Days 29, 57, 85, and (for cohorts who received 420 mg Tezepelumab/placebo SC or any IV dose) 113.
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-tezepelumab Antibodies
ParticipantsPart A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IVPart A: PlaceboPart B: Tezepelumab 700 mg IVPart B: Placebo IV
Anti-tezepelumab binding antibodies00000000100
Anti-tezepelumab neutralizing antibodies00000000000
SecondaryPart A: Maximum Observed Concentration (Cmax) of Tezepelumab

The maximum observed serum concentration of tezepelumab was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.
Reported as:
Mean · μg/mL
Part A: Maximum Observed Concentration (Cmax) of Tezepelumab
μg/mLPart A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IV
Part A: Maximum Observed Concentration (Cmax) of Tezepelumab0.257 ± 0.08240.792 ± 0.05932.01 ± 0.6207.82 ± 2.2523.6 ± 10.358.0 ± 19.364.4 ± 10.2219 ± 38.3
SecondaryPart A: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab

The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.
Reported as:
Mean · day*μg/mL
Part A: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab
day*μg/mLPart A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IV
Part A: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab8.12 ± 1.9632.9 ± 2.7576.7 ± 31.6278 ± 64.3867 ± 3492050 ± 6271150 ± 1763440 ± 253
SecondaryPart A: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab

The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.
Reported as:
Mean · day*μg/mL
Part A: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab
day*μg/mLPart A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IV
Part A: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab8.69 ± 1.9736.6 ± 4.6084.6 ± 37.9303 ± 70.3976 ± 4092140 ± 6771200 ± 2083530 ± 322
SecondaryPart A: Elimination Half-life (t1/2) of Tezepelumab

Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.
Reported as:
Mean · days
Part A: Elimination Half-life (t1/2) of Tezepelumab
daysPart A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IV
Part A: Elimination Half-life (t1/2) of Tezepelumab19.9 ± 4.8123.4 ± 4.3022.7 ± 4.8122.5 ± 1.3525.7 ± 5.5223.3 ± 2.8924.5 ± 6.2820.7 ± 6.44
SecondaryPart B: Time of Maximum Observed Concentration (Tmax) of Tezepelumab

Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.
Reported as:
Median · hours
Part B: Time of Maximum Observed Concentration (Tmax) of Tezepelumab
hoursPart B: Tezepelumab 700 mg IV
Part B: Time of Maximum Observed Concentration (Tmax) of Tezepelumab4.08 (1.00 to 8.12)
SecondaryPart B: Maximum Observed Concentration (Cmax) of Tezepelumab

Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.
Reported as:
Mean · μg/mL
Part B: Maximum Observed Concentration (Cmax) of Tezepelumab
μg/mLPart B: Tezepelumab 700 mg IV
Part B: Maximum Observed Concentration (Cmax) of Tezepelumab253 ± 57.2
SecondaryPart B: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab

The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.
Reported as:
Mean · day*μg/mL
Part B: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab
day*μg/mLPart B: Tezepelumab 700 mg IV
Part B: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab3660 ± 990
SecondaryPart B: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab

The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.
Reported as:
Mean · day*μg/mL
Part B: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab
day*μg/mLPart B: Tezepelumab 700 mg IV
Part B: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab3830 ± 1230
SecondaryPart B: Elimination Half-life (t1/2) of Tezepelumab

Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.

Time frame:
Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.
Reported as:
Mean · days
Part B: Elimination Half-life (t1/2) of Tezepelumab
daysPart B: Tezepelumab 700 mg IV
Part B: Elimination Half-life (t1/2) of Tezepelumab22.2 ± 4.72
SecondaryPart B: Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Eczema Area and Severity Index (EASI 50) Score

EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = \< 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.

Time frame:
Baseline and days 15, 29, 43, 57, 85, and 113
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Eczema Area and Severity Index (EASI 50) Score
percentage of participantsPart B: Tezepelumab 700 mg IVPart B: Placebo
Day 15220
Day 29220
Day 432233
Day 57220
Day 85500
Day 1133333
At any postdose time point5633
SecondaryPart B: Percentage of Participants Achieving at Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) Score

EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = \< 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.

Time frame:
Baseline and days 15, 29, 43, 57, 85, and 113
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Achieving at Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) Score
percentage of participantsPart B: Tezepelumab 700 mg IVPart B: Placebo
Day 1500
Day 2900
Day 4300
Day 57110
Day 85130
Day 113220
At any postdose time point220
SecondaryPart B: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score

EASI is a tool used to measure the severity of AD. The index involves an assessment of the intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale from 0 (none) to 3 (severe). The percent affected area for each of the 4 body areas is assessed on a 6-point scale from 0 (0%) to 6 (90% to 100%). The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score is the sum of the scores for each body region, and ranges from 0 to 72, with higher scores indicating greater disease severity. Percent change from baseline = \[(Post-baseline Value - Baseline Value) / Baseline Value\] x 100. A negative change from baseline indicates improvement.

Time frame:
Baseline and days 15, 29, 43, 57, 85, and 113
Reported as:
Mean · percent change
Part B: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score
percent changePart B: Tezepelumab 700 mg IVPart B: Placebo
Day 15-12.47 ± 43.3215.10 ± 55.84
Day 29-23.61 ± 32.82-25.03 ± 20.38
Day 43-17.04 ± 44.28-32.41 ± 31.81
Day 57-22.83 ± 41.23-1.89 ± 37.24
Day 85-31.70 ± 42.14-23.01 ± 21.16
Day 113-25.25 ± 49.40-11.28 ± 54.63
SecondaryPart B: Change From Baseline in Investigator's Global Assessment (IGA)

IGA score is a static 6-point measure of disease activity based on an overall assessment of skin lesions. The IGA was scored on a scale of 0 to 5, where 0 (clear) = no inflammatory signs of AD; 1. (almost clear) = just perceptible erythema and just perceptible papulation/infiltration; 2. (mild) = mild erythema and mild papulation and infiltration; 3. (moderate) = moderate erythema and moderate papulation and infiltration; 4. (severe) = severe disease with severe erythema and severe papulation and infiltration; 5. (very severe) = severe disease with severe erythema and severe papulation and infiltration with oozing/crusting. A negative change from baseline indicates improvement.

Time frame:
Baseline and days 15, 29, 43, 57, 85, and 113
Reported as:
Mean · scores on a scale
Part B: Change From Baseline in Investigator's Global Assessment (IGA)
scores on a scalePart B: Tezepelumab 700 mg IVPart B: Placebo
Day 15-0.33 ± 0.500.33 ± 0.58
Day 29-0.56 ± 0.73-0.67 ± 0.58
Day 43-0.44 ± 0.53-1.00 ± 0.00
Day 57-0.44 ± 0.73-1.00 ± 0.00
Day 85-0.63 ± 0.74-1.33 ± 0.58
Day 113-0.44 ± 0.73-0.33 ± 1.15

Adverse events

Collected over For Part A Tezepelumab/Placebo 2.1 mg, 7 mg, 21 mg, 70 mg, and 210 mg SC: 85 days. For Part A Tezepelumab/Placebo 420 mg SC, 210 mg IV, and 700 mg IV and Part B: 113 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Tezepelumab 2.1 mg SC—0/6 (0%)3/6 (50%)
Part A: Tezepelumab 7 mg SC—0/6 (0%)5/6 (83.3%)
Part A: Tezepelumab 21 mg SC—0/6 (0%)1/6 (16.7%)
Part A: Tezepelumab 70 mg SC—0/6 (0%)6/6 (100%)
Part A: Tezepelumab 210 mg SC—0/6 (0%)2/6 (33.3%)
Part A: Tezepelumab 420 mg SC—0/6 (0%)3/6 (50%)
Part A: Tezepelumab 210 mg IV—0/6 (0%)4/6 (66.7%)
Part A: Tezepelumab 700 mg IV—0/6 (0%)5/6 (83.3%)
Part A: Placebo SC—0/12 (0%)8/12 (66.7%)
Part A: Placebo IV—0/4 (0%)3/4 (75%)
Part B: Tezepelumab 700 mg IV—0/9 (0%)7/9 (77.8%)
Part B: Placebo IV—1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventPart A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IVPart A: Placebo SCPart A: Placebo IVPart B: Tezepelumab 700 mg IVPart B: Placebo IV
INFECTIONInfections and infestations0/60/60/60/60/60/60/60/60/120/40/91/3
PROCEDURAL PAINInjury, poisoning and procedural complications0/60/60/60/60/60/60/60/60/120/40/91/3
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPart A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IVPart A: Placebo SCPart A: Placebo IVPart B: Tezepelumab 700 mg IVPart B: Placebo IV
INSOMNIAPsychiatric disorders0/60/60/60/60/61/60/60/60/120/41/92/3
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/62/60/63/60/60/61/61/64/121/42/91/3
HEADACHENervous system disorders1/62/60/63/60/60/60/61/60/121/40/90/3
CONJUNCTIVITISEye disorders0/60/60/60/60/60/60/60/60/120/40/91/3
ANIMAL BITEInjury, poisoning and procedural complications0/60/60/60/60/60/60/60/60/120/40/91/3
JOINT INJURYInjury, poisoning and procedural complications0/60/60/60/60/60/60/60/60/120/40/91/3
POST PROCEDURAL COMPLICATIONInjury, poisoning and procedural complications0/60/60/60/60/60/60/60/60/120/40/91/3
MYALGIAMusculoskeletal and connective tissue disorders1/60/60/61/60/60/62/60/60/120/40/90/3
DIZZINESSNervous system disorders0/60/60/61/61/60/60/60/60/120/40/91/3
LIBIDO DECREASEDPsychiatric disorders0/60/60/60/60/60/60/60/60/120/40/91/3

Baseline characteristics

Participants who received at least 1 dose of Investigational product.

Age, Continuous
Age, Continuous(years)Part A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IVPart A: PlaceboPart B: Tezepelumab 700 mg IVPart B: Placebo IVTotal
Mean28.2 ± 4.932.2 ± 2.136.8 ± 2.628.3 ± 4.933.7 ± 4.137.0 ± 3.733.0 ± 7.530.2 ± 3.632.3 ± 7.648.1 ± 11.345.3 ± 5.534.8 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IVPart A: PlaceboPart B: Tezepelumab 700 mg IVPart B: Placebo IVTotal
Female1251001132016
Male54156655137360
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Tezepelumab 2.1 mg SCPart A: Tezepelumab 7 mg SCPart A: Tezepelumab 21 mg SCPart A: Tezepelumab 70 mg SCPart A: Tezepelumab 210 mg SCPart A: Tezepelumab 420 mg SCPart A: Tezepelumab 210 mg IVPart A: Tezepelumab 700 mg IVPart A: PlaceboPart B: Tezepelumab 700 mg IVPart B: Placebo IVTotal
White1102322248227
Black or African American200001021017
Hispanic or Latino35542241110037
Asian001001000103
Other000010010002
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Parnes JR, Sullivan JT, Chen L, Dias C. Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects. Clin Pharmacol Ther. 2019 Aug;106(2):441-449. doi: 10.1002/cpt.1401. Epub 2019 Mar 23. PubMed 30779339 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2008 to primary completion in Jan 2011, 27 months.

Results were first posted in Jul 2022, 11 years 6 months after primary completion.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 27 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2008
First posted
Sep 22, 2008
StartActual
Sep 18, 2008
Primary completionActual
Jan 5, 2011
CompletionActual
Jan 5, 2011
Results first posted
Jul 18, 2022
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00757042
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 22, 2008
Start date
Sep 18, 2008
Primary completion
Jan 5, 2011
Completion
Jan 5, 2011
Results posted
Jul 18, 2022
Last update
Sep 21, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion